NIDDM PRIMARY PREVENTION TRIAL (DPT-2)

  • Hazuda, Helen P (PI)
  • Haffner, Steven M. (PI)

Project: Research project

Project Details

Description

As part of a multi-center grant we will attempt to prevent the
development of NIDDM in 200 subjects with impaired glucose tolerance.
The overall study will involve 20 clinical centers and 4000 subjects.
This proposal will take seven years, with a one year protocol
development, five year clinical trial and one year evaluation period.
The proposed intervention will be a factorial design with one factor
being diet and exercise versus usual cre and the second factor being an
insulin sensitizer (e.g. Metformin) versus placebo. The primary endpoint
will be the development of NIDDM. Secondary endpoints include changes
in lipids, lipoproteins, ankle/arm ratio, urinary albumin and carotid
wall thickness. Subjects will be obtained by several methods including:
a) community advertising through radio and television advertisements; b)
selective screening based on blood glucose from the Brady Green clinic;
and c) subjects from the San Antonio Heart Study. Subjects identified
with newly discovered diabetes but with normal fasting glycemia (2-hr
glucose greater than or equal to 200 mg/dl, but fasting glucose
StatusFinished
Effective start/end date9/22/941/31/16

Funding

  • National Institutes of Health: $301,405.00
  • National Institutes of Health: $346,703.00
  • National Institutes of Health: $500,697.00
  • National Institutes of Health: $589,885.00
  • National Institutes of Health: $430,521.00
  • National Institutes of Health: $628,431.00
  • National Institutes of Health: $629,668.00

ASJC

  • Medicine(all)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.